Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

alitretinoin

An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:9-cis retinoic acid
9-cis-retinoic acid
retinoicacid-9-cis
US brand name:Panretin
Foreign brand name:Panretyn
Panrexin
Abbreviation:9-cRA
Acronym:9-cis-RA
Code name:ALRT 1057
ALRT-1057
ALRT1057
LGD 1057
LGD-1057
LGD1057
Chemical structure:3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-trans-4-trans-6-cis-8-trans-nonatetraenoic acid
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search